SCHEMBL30210342

SCHEMBL30210342

CN(C(=O)OC(C)(C)C)[C@@H]1CN(C(=O)OCc2ccccc2)CC12CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CYP2C19 P33261 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 1/20 0.39
PARP1 P09874 1/20 0.39
JAK2 O60674 2/20 0.39
JAK1 P23458 2/20 0.39
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTR2C P28335 1/20 0.38
PDE4B Q07343 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20520922 0.85 SMN1; SMN2 (0.48) RORCSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL34474162 0.85 SMN1; SMN2 (0.48) RORCSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL31210928 0.81 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL14428326 0.80 JAK2 (0.47) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL31633880 0.80 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL9178846 0.80 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL25171385 0.80 JAK2 (0.43) RORCJAK2JAK1PDK1PDK2
SCHEMBL22436187 0.79 SIGMAR1 (0.44) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL30911323 0.79 SIGMAR1 (0.44) SMN1; SMN2NPC1RAB9ACYP2C19MEN1
SCHEMBL24510038 0.79 SIGMAR1 (0.44) SMN1; SMN2NPC1RAB9ACYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
EP-4139299-B1 KRAS G12D PROTEIN INHIBITORS TAIHO PHARMACEUTICAL CO LTD (JP) 2025-12-17 EP disclosed
US-20230174518-A1 KRAS G12D PROTEIN INHIBITORS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-06-08 US disclosed
EP-4139299-A1 KRAS G12D PROTEIN INHIBITORS Taiho Pharmaceutical Co., Ltd. (JP) 2023-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174518-A1 KRAS G12D PROTEIN INHIBITORS KRAS, NRAS, HRAS RORC 2826/4885SMN1; SMN2 3079/4885NPC1 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.